Roche trials database

Trial information

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Status:

Recruiting

Protocol number:

NP28266

Sponsor:

Hoffmann-La Roche

Company division:

Pharmaceutical

Official Scientific Title:

Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus with or without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naïve or Null Responders to Previous Interferon-Based Treatment

Brief summary:

This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731, RO5190591, ritonavir and Copegus (ribavirin) with or without RO5024048 in patients with chronic hepatitis C genotype 1. In Part 1, treatment-naïve patients will be randomized to receive treatment with RO5466731, RO5190591 plus ritonavir, and Copegus, with or without RO5024048. In Part 2, further treatment-naïve patients will receive a successful regimen from Part 1, or a reduced intensity regimen, and patients who have previously experienced null response to interferon-based treatment will be added to the study. Target sample size is 180.

Study phase:

II

Study type:

Interventional; Treatment; Randomized; Parallel study

Conditions:

• Hepatitis C, Chronic

Intervention type:

Drug

Intervention name:

RO5466731

Primary outcome:

1. Sustained virological response (defined as undetectable serum HCV RNA) 12 weeks after end of treatment Time frame: approximately 20 months
2. Safety: Incidence of adverse events Time frame: approximately 20 months

Key secondary outcomes:

1. Antiviral activity: Change in serum HCV RNA levels Time frame: from baseline to 24 weeks after end of treatment
2. Pharmacokinetics in coadministration: Area under the concentration-time curve (AUC) Time frame: Pre-dose Weeks 1, 2, 3, 4, 6, 10, and 12 and up to 12 hours post-dose Weeks 1, and 4 or 3 and 6
3. HCV drug resistance Time frame: approximately 20 months
4. Quality of life: Short-Form 36v2/Brief Fatigue Inventory questionnaires Time frame: approximately 20 months

Inclusion criteria:

• Adult patients, >/= 18 years of age
• Chronic hepatitis C genotype 1 of >/= 6 months duration at screening
• Part 1 and Part 2: Naïve to treatment with interferon (pegylated or non-pegylated). Patients who have participated in studies investigating a direct-acting antiviral agent with or without interferon are excluded
• Part 2: Treatment experienced patients having a previous null response to treatment with interferon containing regimen
• Liver biopsy or non-invasive (e.g. Fibroscan) evaluation in the past 24 calendar months showing absence of cirrhosis or incomplete/transition to cirrhosis
• Body mass index (BMI) 18 to 35 kg/m2 inclusive and body weight >/= 45 kg

Exclusion criteria:

• Pregnant or lactating women or males with female partners who are pregnant or lactating
• Decompensated liver disease or impaired liver function (as defined by protocol)
• Cirrhosis or incomplete/transition to cirrhosis
• Non- hepatitis C chronic liver disease
• Positive for hepatitis B or HIV infection
• History of pre-existing renal disease
• History of severe cardiac disease
• History of neoplastic disease within the last 5 years, except for localized or in situ carcinoma of the skin
• History of drug abuse within the last year; history of cannabinoid use is not excluded
• Evidence of alcohol abuse within 1 year of screening and consumption of more than 2 units of alcohol per day
• Medical condition that requires use of systemic corticosteroids
• Received warfarin or other anticoagulants during the 21 days immediately prior to screening or is expected to require warfarin or other anticoagulants during the study
• Anticipated use or need for significant medical treatment during the study or use of concomitant medications or nutrients that are excluded by protocol (e.g. drugs that are contraindicated with ritonavir, hormonal methods of contraception)

Gender:

Males or Females

Age limits:

Min: 18 years Max: N/A (No limit)

Accepts healthy volunteers:

No

Anticipated start date:

June, 2012

Trial registration date:

27.03.2012

Date last updated:

06.05.2013

This trial is being conducted at the following locations:

Australia

• HERSTON
• KINGSWOOD
• PARKVILLE
• SYDNEY

Germany

• BERLIN
• FRANKFURT AM MAIN
• HAMBURG
• HANNOVER

New Zealand

• AUCKLAND
• DUNEDIN
• HAMILTON

Poland

• BIALYSTOK
• CHORZOW
• LODZ
• MYSLOWICE

U.S.A.

• LAJOLLA, CA
• ENGLEWOOD, CO
• SOUTH MIAMI, FL
• MARIETTA, GA
• HONOLULU, HI
• CHICAGO, IL
• KANSAS CITY, KS
• DETROIT, MI
• SAINT LOUIS, MO
• ASHEVILLE, NC
• DALLAS, TX
• FORT SAM HOUSTON, TX
• HOUSTON, TX
• SAN ANTONIO, TX
• VANCOUVER, WA

Link to trial result